

COURS INTERNATIONAL

3RD COURSE ON BREAST CANCER - 2017

Description of course:



This course focuses on breast cancers both on a biological and a clinical point of view. It will cover the biology of breast cancers from stem cell biology to metastatic process encompassing special courses on diagnostic of the disease, the state -of art of treatment with presentation of clinical trials and modalities of follow-up. A special focus will emphasize the recent data on oestrogen resistance, basal-like and hereditary breast cancers, their new therapeutic strategies and what next generation sequencing provides in breast cancer biology and clinical management.

Organizers: Roman Rouzier, Anne Vincent-Salomon and Jean-Yves Pierga

[Discover some conferences](#)

[20170615_programme.pdf](#)

[important_how_to_register_to_this_course.pdf](#)

Audience:

- . Interns
- . Chief resident
- . PhDs
- . Postdocs

All conferences will be in English.

Conditions of selection:

The selection will be made according to resumes.

Every participant will have to present a scientific article related to the topics discussed. The Articles will be given to the students before the course begins. Participants will also present their research work in poster sessions scheduled during the week.

Application deadline:

15 May 2017

Location:

Institut Curie - Paris

Results of selection:

April 2017

Registration fees:

No registration fees are requested.

Foreign students or French students living outside the Parisian area can apply for travel fellowships. So please include a justification with your application.

Organizers:

Roman Rouzier, Jean-Yves Pierga, François-Clément Bidard, Paul-Henri Cottu, Anne Vincent-Salomon, Marc-Henri Stern, Fatima Mechta-Grigoriou, Stephan Vagner, Philippe Chavrier, Deborah Bourc'his, Raphaël Margueron.

Contact:

c.breastcancer2017@curie.fr

Topics:

Diagnosis and clinical management
Genomics and Epigenomics
Stroma
Endocrine resistance - metastatic development
Preclinical models - TNBC
Industrial research

Sponsors:

Roche
Leica
Pfizer
AstraZeneca
PACRI